Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

17:40 EDT 24th July 2014 | BioPortfolio

Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Conditions

Herpes Zoster

Intervention

Herpes Zoster Vaccine GSK 1437173A

Location

GSK Investigational Site
Randwick
New South Wales
Australia
2031

Status

Active, not recruiting

Source

GlaxoSmithKline

Results (where available)

View Results

Links

Clinical Trials [1234 Associated Clinical Trials listed on BioPortfolio]

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as...

VZV PCR Sampling Validation Study

This study will evaluate and compare various methods for collecting lesion samples from subjects with clinically diagnosed herpes zoster for the laboratory confirmation of herpes zoster. T...

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster

The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to subjects with a history of herpes zoster.

A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

The purpose of this study is to determine the pharmacokinetics and dosage of EPB-348 that best balances safety and efficacy among adult immunocompetent patients with an acute episode of he...

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune respon...

PubMed Articles [1836 Associated PubMed Articles listed on BioPortfolio]

Herpes zoster caused by vaccine strain varicella zoster virus in an immunocompetent recipient of zoster vaccine.

We report the first laboratory-documented case of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a 68 year old immunocompetent adult with strong evidence...

Increased risk of cardiovascular events in patients with herpes zoster: A population-based study.

The association between herpes zoster and cardiovascular complications remains vague with limited study on the association between these two disorders. This study evaluated the risk of cardiovascular...

The clinical and epidemic characteristics of shingles (herpes zoster) and its prevention with vaccines.

The review gives data on the clinical manifestations, complications, and epidemiological characteristics of herpes zoster. It discusses prospects for and foreign experience with vaccination against ch...

Disseminated herpes zoster ophthalmicus in an immunocompetent 8-year old boy.

Varicella results from a primary infection with the varicella virus while herpes zoster is caused by a reactivation of a latent infection. Dissemination of herpes zoster is uncommon in immunocompetent...

ANALYSIS OF T CELL RESPONSES DURING ACTIVE VARICELLA ZOSTER VIRUS REACTIVATION IN HUMAN GANGLIA.

Varicella zoster virus (VZV) is responsible for both varicella (chickenpox) and herpes zoster (shingles). During varicella the virus establishes latency within the sensory ganglia and can reactivate t...

Medical and Biotech [MESH] Definitions

An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.

Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.

HERPES ZOSTER but without eruption of vesicles. Patients exhibit the characteristic pain minus the skin rash, sometimes making diagnosis difficult.

An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)

Inflammation of brain tissue caused by infection with the varicella-zoster virus (HERPESVIRUS 3, HUMAN). This condition is associated with immunocompromised states, including the ACQUIRED IMMUNODEFICIENCY SYNDROME. Pathologically, the virus tends to induce a vasculopathy and infect oligodendrocytes and ependymal cells, leading to CEREBRAL INFARCTION, multifocal regions of demyelination, and periventricular necrosis. Manifestations of varicella encephalitis usually occur 5-7 days after onset of HERPES ZOSTER and include HEADACHE; VOMITING; lethargy; focal neurologic deficits; FEVER; and COMA. (From Joynt, Clinical Neurology, 1996, Ch 26, pp29-32; Hum Pathol 1996 Sep;27(9):927-38)

More From BioPortfolio on "Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults"

Search BioPortfolio:

Relevant Topic

Vaccine · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one...

Advertisement
Advertisement